Isabella C. Glitza

Oct 15, 2024 | digitalcommons.library.tmc.edu | Isabella C. Glitza |Yongwoo David Seo |Christine Spencer |Jennifer Wortman

Gut-microbiota modulation shows promise in improving immune-checkpoint blockade (ICB) response; however, precision biomarker-driven, placebo-controlled trials are lacking. We performed a multicenter, randomized placebo-controlled, biomarker-stratified phase I trial in patients with ICB-naïve metastatic melanoma using SER-401, an orally delivered Firmicutesenriched spore formulation.